Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Limited has announced its 2025 Annual General Meeting, scheduled for October 23, 2025. The announcement includes details such as the AGM notice, proxy form, shareholder question form, and an online guide from Link Market Services. This meeting and the accompanying 2025 Annual Report, which includes the Corporate Governance Statement, are significant for stakeholders as they provide insights into the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for various clients, including doctors, specialists, patients, hospitals, and corporate entities. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on combining skilled personnel, medical and scientific leadership, and innovative technologies to enhance decision-making and improve patient outcomes.
Average Trading Volume: 909,315
Technical Sentiment Signal: Sell
Current Market Cap: A$489.5M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.